Amgen Inc. (AMGN: Quote) said Wednesday it plans to build a new manufacturing facility in the Tuas Biomedical Park area of Singapore. Over the next several years, Amgen anticipates investing about $200 million to build an innovative new facility, which will initially focus on expanding Amgen’s manufacturing capability for monoclonal antibodies. The facility will be capable of manufacturing both clinical and commercial products.
Construction is expected to begin in the next few months. Amgen is currently partnering with local universities to recruit for a number of positions in Manufacturing and Quality.
Click here to receive FREE breaking news email alerts for Amgen Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.comBusiness News